H1B Salary Data

Home › Employers › Carenow Pharmacy II LLC

Carenow Pharmacy II LLC: H-1B salaries and sponsorship

Carenow Pharmacy II LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $55,000.

Applications (LCAs)3
Certified3
Employer addressMount Dora, FL
H-1B dependent employerNo
Median offered salary$55,000
Middle half of salaries$54,950–$91,850
10th–90th percentile$54,920–$113,960

Does Carenow Pharmacy II LLC sponsor H-1B visas?

Carenow Pharmacy II LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 6, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Pharmacist-in-Charge1$128,700
Pharmacy Operation Manager1$54,900
Regulatory Affairs Specialist1$55,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20231$128,700
FY20251$54,900
FY20261$55,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Regulatory Affairs Specialist$55,000–$70,000
Level II
Mount Dora, FLApr 6, 2026Oct 1, 2026Certified
Pharmacy Operation Manager$54,900–$56,800
Level I
Mount Dora, FLMay 19, 2025Oct 1, 2025Certified
Pharmacist-in-Charge$128,700
Level III
Mount Dora, FLNov 18, 2022Nov 28, 2022Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).